FOXO3 and neuroblastoma: In the present study, we demonstrate for the first time that FOXO3 elevates the migratory capacity of NB cells via LUM expression and characterize the FDA-approved compound RPG as a novel FOXO3 inhibitor that efficiently represses the metastatic potential of neuronal cancer cells.